Download
s12967-020-02565-9.pdf 728,05KB
WeightNameValue
1000 Titel
  • Mesenchymal stromal cells for osteonecrosis
1000 Autor/in
  1. Elgaz, Suemeyye |
  2. Bonig, H. |
  3. Bader, P. |
1000 Erscheinungsjahr 2020
1000 Publikationstyp
  1. Artikel |
1000 Online veröffentlicht
  • 2020-10-20
1000 Erschienen in
1000 Quellenangabe
  • 18(1):399
1000 Copyrightjahr
  • 2020
1000 Lizenz
1000 Verlagsversion
  • https://doi.org/10.1186/s12967-020-02565-9 |
  • https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7576732/ |
1000 Publikationsstatus
1000 Sprache der Publikation
1000 Abstract/Summary
  • Osteonecrosis (ON) is an acquired debilitating skeletal disorder, which is caused by a multitude of traumatic and non-traumatic etiological factors. Vascular damage, mechanical stress and increased intraosseous pressure have been discussed as contributors to ON. The optimal treatment of ON remains to be determined, since the current gold standard, core decompression, is insufficiently effective. Specific properties of mesenchymal stromal cells (MSCs) provide the rationale for their assessment in advanced stages of ON: Osteoinductive potential has been demonstrated and MSC preparations of suitable quality for use as medicinal products have been developed. Here we review the scant information on the use of allogeneic or autologous MSCs in advanced ON as well as potentially supportive data from pre-clinical studies with autologous bone marrow mononuclear cells (auto BM-MNCs), which have been studied quite extensively and the presumed therapeutic effect of which was attributed to the rare MSCs contained in these cell products. Outcomes in clinical trials with MSCs and auto-BM-MNCs remain preliminary and non-definitive, at best promising, with respect to their pharmacological effect. Clearly, though, the application of any of these cell therapies was technically feasible and safe in that it was associated with low complication rates. The heterogeneity of cell type and source, study protocols, cell manufacturing, cell properties, cell doses and surgical techniques might contribute to inconsistent results.
1000 Sacherschließung
lokal Cell-based therapies
lokal Osteonecrosis
lokal Humans [MeSH]
lokal Mesenchymal Stem Cell Transplantation [MeSH]
lokal Review
lokal Mesenchymal stromal cells (MSC)
lokal Osteonecrosis/therapy [MeSH]
lokal Cell, tissue and gene therapy
lokal Cell- and Tissue-Based Therapy [MeSH]
lokal Bone Marrow Cells [MeSH]
lokal Mesenchymal Stem Cells [MeSH]
1000 Liste der Beteiligten
  1. https://orcid.org/0000-0002-9118-1163|https://frl.publisso.de/adhoc/uri/Qm9uaWcsIEgu|https://frl.publisso.de/adhoc/uri/QmFkZXIsIFAu
1000 Hinweis
  • DeepGreen-ID: 69c9a75b3d674b759f400c70207b8dba ; metadata provieded by: DeepGreen (https://www.oa-deepgreen.de/api/v1/), LIVIVO search scope life sciences (http://z3950.zbmed.de:6210/livivo), Crossref Unified Resource API (https://api.crossref.org/swagger-ui/index.html), to.science.api (https://frl.publisso.de/), ZDB JSON-API (beta) (https://zeitschriftendatenbank.de/api/), lobid - Dateninfrastruktur für Bibliotheken (https://lobid.org/resources/search)
1000 Label
1000 Dateien
  1. Mesenchymal stromal cells for osteonecrosis
1000 Objektart article
1000 Beschrieben durch
1000 @id frl:6464855.rdf
1000 Erstellt am 2023-11-16T07:22:14.607+0100
1000 Erstellt von 322
1000 beschreibt frl:6464855
1000 Zuletzt bearbeitet 2023-12-01T01:00:36.054+0100
1000 Objekt bearb. Fri Dec 01 01:00:36 CET 2023
1000 Vgl. frl:6464855
1000 Oai Id
  1. oai:frl.publisso.de:frl:6464855 |
1000 Sichtbarkeit Metadaten public
1000 Sichtbarkeit Daten public
1000 Gegenstand von

View source